Agile Therapeutics, Inc.

OTCPK:AGRX Stok Raporu

Piyasa değeri: US$10.4m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Agile Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Agile Therapeutics has been growing earnings at an average annual rate of 7.8%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 66.5% per year.

Anahtar bilgiler

7.8%

Kazanç büyüme oranı

35.0%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi6.0%
Gelir büyüme oranı66.5%
Özkaynak getirisin/a
Net Marj-73.5%
Son Kazanç Güncellemesi30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Agile appoints chief commercial officer from within ranks amid leadership revamp

Oct 10

Agile gains as H.C. Wainwright sees 630% upside potential

Jul 11

Agile Therapeutics prices $24M upsized stock offering

Jul 01

Agile Therapeutics: Twirla's Lackluster Launch Forces Me To Change My Strategy

Apr 04

Agile Therapeutics: Bullish On Capitulation And Max Pain

Oct 19

Agile Therapeutics: Another Quarter Of Progress And Another Opportunity To Buy

Jul 30

Agile Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 06

How Many Agile Therapeutics, Inc. (NASDAQ:AGRX) Shares Did Insiders Buy, In The Last Year?

Feb 25
How Many Agile Therapeutics, Inc. (NASDAQ:AGRX) Shares Did Insiders Buy, In The Last Year?

Agile Therapeutics issues cash projection at JP Morgan healthcare conference

Jan 14

Assessing Agile Therapeutics

Jan 10

How Many Agile Therapeutics, Inc. (NASDAQ:AGRX) Shares Do Institutions Own?

Jan 04
How Many Agile Therapeutics, Inc. (NASDAQ:AGRX) Shares Do Institutions Own?

Agile Therapeutics announces peer-reviewed publication of late-stage study for Twirla contraception patch

Nov 30

Agile Therapeutics EPS in-line

Nov 12

Gelir ve Gider Dağılımı

Agile Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

OTCPK:AGRX Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 2422-16252
31 Mar 2421-8272
31 Dec 2320-14282
30 Sep 2320-14323
30 Jun 2316-19333
31 Mar 2313-20353
31 Dec 2211-25423
30 Sep 228-41505
30 Jun 227-52545
31 Mar 226-64605
31 Dec 214-71586
30 Sep 213-69568
30 Jun 212-685410
31 Mar 211-614512
31 Dec 201-523614
30 Sep 200-402513
30 Jun 200-291612
31 Mar 200-221210
31 Dec 190-19910
30 Sep 190-1679
30 Jun 190-1678
31 Mar 190-1879
31 Dec 180-20910
30 Sep 180-221011
30 Jun 180-261212
31 Mar 180-281314
31 Dec 170-281214
30 Sep 170-271117
30 Jun 170-281019
31 Mar 170-29921
31 Dec 160-29921
30 Sep 160-27922
30 Jun 160-29825
31 Mar 160-29825
31 Dec 150-30726
30 Sep 150-33724
30 Jun 150-30621
31 Mar 150-25617
31 Dec 140-16513
30 Sep 140-12410
30 Jun 140-947
31 Mar 140-1037

Kaliteli Kazançlar: AGRX is currently unprofitable.

Büyüyen Kar Marjı: AGRX is currently unprofitable.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: AGRX is unprofitable, but has reduced losses over the past 5 years at a rate of 7.8% per year.

Büyüme Hızlandırma: Unable to compare AGRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: AGRX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13%).


Özkaynak Getirisi

Yüksek ROE: AGRX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin